Ni Dan, Madden Timothy L, Johansen Mary, Felix Edward, Ho Dah H, Newman Robert A
Pharmaceutical Development Center, University of Texas M.D. Anderson Cancer Center, 8000 El Rio, Houston, TX 77054, USA.
J Exp Ther Oncol. 2002 Sep-Oct;2(5):278-85. doi: 10.1046/j.1359-4117.2002.01052.x.
Pharmacokinetic studies of [3H]oleandrin, a cardiac glycoside component of Anvirzel, were conducted in mice after either an i.v. dose (40 micrograms/kg) or a p.o. dose (80 micrograms/kg). Oleandrin was rapidly absorbed after oral dosing (Cmax at 20 min) although the elimination half-life was longer (2.3 +/- 0.5 h) than that after i.v. dosing (0.4 +/- 0.1 h). The AUC0-infinity values obtained after i.v. and p.o. dosing were 24.6 +/- 11.1 and 14.4 +/- 4.3 (ng.h/ml), respectively, resulting in an oral bioavailability of approximately 30%. After i.v. administration, oleandrin concentration in liver was approximately twice that measured in heart or kidney tissue. Oleandrigenin, the aglycone of oleandrin, was also found in these tissues. At 5 min, > 60% of the total radioactivity in liver was due to oleandrin while 28% of the given dose was present as oleandrigenin. Twenty-four hours following injection, 8% of total radioactivity was excreted in urine and contained both oleandrigenin (4.4% of the injected dose) and oleandrin (1.9%). Sixty-six percent of injected radioactivity was found in feces and consisted of oleandrin and oleandrigenin in equal amounts. Uptake of oleandrin in brain after i.p. injection of oleandrin (3 mg/kg) or oleander extract (700 mg/kg) was examined. Measured by LC/MS/MS, oleandrin content in brain was higher following injection of extract than it was with an equivalent dose of oleandrin. The data suggest that components within oleander extract may enhance transport of oleandrin across the blood brain barrier.
对强心苷类药物安维尔(Anvirzel)的成分[3H]夹竹桃苷元进行了药代动力学研究,分别对小鼠静脉注射(40微克/千克)或口服给药(80微克/千克)。口服给药后夹竹桃苷元吸收迅速(20分钟时达到Cmax),尽管消除半衰期(2.3±0.5小时)比静脉注射给药后(0.4±0.1小时)长。静脉注射和口服给药后获得的AUC0-无穷大值分别为24.6±11.1和14.4±4.3(纳克·小时/毫升),导致口服生物利用度约为30%。静脉注射后,肝脏中夹竹桃苷元的浓度约为心脏或肾脏组织中测量值的两倍。在这些组织中也发现了夹竹桃苷元的苷元夹竹桃次苷元。在5分钟时,肝脏中总放射性的>60%归因于夹竹桃苷元,而给药剂量的28%以夹竹桃次苷元的形式存在。注射后24小时,8%的总放射性从尿液中排出,其中同时含有夹竹桃次苷元(注射剂量的4.4%)和夹竹桃苷元(1.9%)。66%的注射放射性在粪便中发现,由等量的夹竹桃苷元和夹竹桃次苷元组成。检查了腹腔注射夹竹桃苷元(3毫克/千克)或夹竹桃提取物(700毫克/千克)后夹竹桃苷元在脑中的摄取情况。通过LC/MS/MS测量,注射提取物后脑中夹竹桃苷元的含量高于等量夹竹桃苷元注射后的含量。数据表明夹竹桃提取物中的成分可能会增强夹竹桃苷元穿过血脑屏障的转运。